Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06768658 · ClinicalTrials.gov registry record · Phase 1
A Study of TAK-951 in Participants With Cyclic Vomiting Syndrome (CVS)
A Phase 1 study, sponsored by Takeda.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT06768658: Clinical Trial Phase 1 study, sponsored by Takeda.
NCT06768658 is a Phase 1 study that was terminated before completion, run by Takeda. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06768658, a Phase 1 study, was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a study of TAK-951 in participants with cyclic vomiting syndrome (CVS). The main aims of this study are as follows: * To check for side effects from treatment with TAK-951. * To learn how much TAK-951 participants can receive without getting side effects from it. * To check how much TAK-951 stays in the blood over time to work out the best dose. * The dose of TAK-951 will be checked to see how much stays in their blood over time. * To see if it is possible to give treatment at home. Participants will be given TAK-951 injected just under the skin (subcutaneous or SC).
Primary Outcome
A TEAE was defined as an adverse event (AE) with an onset that occurs after receiving study drug. An AE was defined as any untoward medical occurrence in a clinical investigation participant who has signed informed consent to participate in a study; it does not necessarily have to have a causal relationship with the treatment. An AE could therefore be any unfavorable and unintended sign (example, a clinically significant abnormal vital sign or laboratory finding), symptom, or disease temporally
Interventions
- DRUG TAK-951
- DRUG TAK-951 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2022-03-02 |
| Est. Completion | 2023-01-09 |
| Phase | Phase 1 |
Why NCT06768658 stopped before completion
NCT06768658 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which TAK-951 is the first listed.
NCT06768658 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06768658 about?
NCT06768658 is a clinical study titled "A Study of TAK-951 in Participants With Cyclic Vomiting Syndrome (CVS)". This is a study of TAK-951 in participants with cyclic vomiting syndrome (CVS). The main aims of this study are as follows: * To check for side effects from treatment with TAK-951. * To learn how much TAK-951 participants can receive without getting side effects from it. * To check how much TAK-95...
What is the current status of trial NCT06768658?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2022-03-02. Estimated completion is 2023-01-09.
What interventions are being tested in trial NCT06768658?
The interventions under investigation include: TAK-951 (DRUG), TAK-951 Placebo (DRUG).
Who is sponsoring clinical trial NCT06768658?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06768658's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI